Document Detail


Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.
MedLine Citation:
PMID:  22788991     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AdΔΔ is an oncolytic adenoviral mutant that has been engineered to selectively target tumors with deregulated cell cycle and apoptosis pathways. AdΔΔ potentiates apoptotic cell death induced by drugs, including mitoxantrone and docetaxel, which are commonly used to treat prostate cancer. Here, we demonstrate that AdΔΔ can also interact synergistically with dietary phytochemicals known to have anti-cancer activities, without incurring the toxic side effects of chemodrugs. Curcumin, genistein, epigallocatechin-gallate, equol, and resveratrol efficiently killed both androgen-receptor positive (22Rv1) and negative cell lines (PC-3, DU145) in combination with adenoviral mutants. Synergistic cell killing was demonstrated with wild-type virus (Ad5) and AdΔΔ in combination with equol and resveratrol. EC(50) values for both phytochemicals and viruses were reduced three- to eightfold in all three combination-treated cell lines. The most potent efficacy was achieved in the cytotoxic drug- and virus-insensitive PC-3 cells, both in vitro and in vivo, while cell killing in normal bronchial epithelial cells was not enhanced. Although equol and resveratrol induced only low levels of apoptosis when administered alone, in combination with wild-type virus or AdΔΔ, the level of apoptotic cell death was significantly increased in PC-3 and DU145 cells. In vivo studies using suboptimal doses of AdΔΔ and equol or resveratrol, showed reduced tumor growth without toxicity to normal tissue. These findings identify novel functions for AdΔΔ and phytochemicals in promoting cancer cell killing and apoptosis, suggesting the use of these natural nontoxic compounds might be a feasible and currently unexploited anti-cancer strategy.
Authors:
Virginie Adam; Maria Ekblad; Katrina Sweeney; Heike Müller; Kristina Hammarén Busch; Camilla Tørnqvist Johnsen; Na Ra Kang; Nick R Lemoine; Gunnel Halldén
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-08-27
Journal Detail:
Title:  Human gene therapy     Volume:  23     ISSN:  1557-7422     ISO Abbreviation:  Hum. Gene Ther.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-17     Completed Date:  2013-02-01     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  9008950     Medline TA:  Hum Gene Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1003-15     Citation Subset:  IM    
Affiliation:
Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae*
Animals
Antineoplastic Agents, Phytogenic / pharmacology*
Apoptosis*
Dietary Supplements*
Equol / pharmacology*
Humans
Male
Mice
Mice, Nude
Mutation*
Neoplasm Transplantation
Oncolytic Viruses*
Phytoestrogens / pharmacology
Prostatic Neoplasms / pathology,  therapy*
Stilbenes / pharmacology*
Transplantation, Heterologous
Grant Support
ID/Acronym/Agency:
C633-A6253/A6251//Cancer Research UK
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Phytoestrogens; 0/Stilbenes; 531-95-3/Equol; Q369O8926L/resveratrol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Screening and selection of Bacillus spp. for fermented corticate soybean meal production.
Next Document:  Biological Evaluation of Dodecaborate-Containing L-Amino Acids for Boron Neutron Capture Therapy.